Cart
sales@molnova.com
Peptide M
CAS No. 110652-62-5
Peptide M( —— )
Catalog No. M30057 CAS No. 110652-62-5
Peptide M is a synthetic Peptide, 50 aa, derived from streptococcus M protein, containing an additional c-terminal cysteine residue.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NamePeptide M
-
NoteResearch use only, not for human use.
-
Brief DescriptionPeptide M is a synthetic Peptide, 50 aa, derived from streptococcus M protein, containing an additional c-terminal cysteine residue.
-
DescriptionPeptide M is a synthetic Peptide, 50 aa, derived from streptococcus M protein, containing an additional c-terminal cysteine residue.
-
In Vitropeptide M is immunogenic in man and provide additional support to the hypothesis that the amino acid sequence which corresponds to peptide M might be involved in uveitic conditions in man.
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number110652-62-5
-
Formula Weight1905.11
-
Molecular FormulaC81H141N21O31
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical NameSequence:Asp-Thr-Asn-Leu-Ala-Ser-Ser-Thr-Ile-Ile-Lys-Glu-Gly-Ile-Asp-Lys-Thr-Val
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
N-Acetylglycine
N-Acetylglycine is a minor constituent of numerous foods with no genotoxicity or acute toxicity. N-acetylglycine is used in biological research of peptidomimetics.
-
Petunidin-3-arabinos...
Petunidin-3-O-arabinoside chloride is an anthocyanin with antioxidant activity that can be isolated from blueberry (Vaccinium Spp.) puree.
-
Remimazolam
Remimazolam is a benzodiazepine derivative drug as an alternative to the short-acting imidazobenzodiazepine midazolam, for use in induction of anaesthesia and conscious sedation for minor invasive procedures.?Remimazolam was found to be both faster acting and shorter lasting than midazolam, and human clinical trials showed a faster recovery time and predictable, consistent pharmacokinetics, suggesting some advantages over existing drugs for these applications.?
